CG Oncology (CGON) Other Operating Expenses (2025 - 2026)

CG Oncology's (CGON) quarterly Other Operating Expenses came in at $3.0 million in Q1 2026, down 3.52% on a QoQ basis from $3.1 million in Q4 2025.

CG Oncology (CGON) Other Operating Expenses (2025 - 2026) Analysis & Trends

CG Oncology (CGON) has 2 years of Other Operating Expenses data on file, last reported at $3.0 million in Q1 2026.

Quarterly Other Operating Expenses changed N/A year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.6 million (changed N/A YoY) and the FY2025 annual result came in at $4.6 million, changed N/A from the prior year.
Other Operating Expenses eased to $3.0 million in Q1 2026, from $3.1 million in the prior quarter.
In the past five years, Other Operating Expenses ranged from a high of $3.1 million in Q4 2025 to a low of $1.6 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	CG Oncology	6.63 Bn	6.63 Bn	-2.77 Mn

Download Data